Career in Sterile Manufacturing, Packing, QC at Cipla - walk in | Only experienced candidates

Cipla is one of the most respected pharmaceutical companies not just in India but across more than 170 countries. Our portfolio includes 2000 products in 65 therapeutic categories with one quality standard globally. Cipla's turnover in FY13 was 1.5 billion USD.

Post : Officers/Associates

Walk in for QA, QC and ADL at Cipla | Only experienced candidates

Cipla’s journey began in 1935 when our founder, Dr. K. A. Hamied, set up an enterprise with the vision to make India self-sufficient in healthcare. Over the past 77 years, we have emerged as one of the world’s most respected pharmaceutical names, not just in India but worldwide.
We have 34 state-of-the-art manufacturing facilities that make Active Pharmaceutical Ingredients (APIs) and formulations, which have been approved by major international Regulatory Agencies. We have over 2000 products in 65 therapeutic categories; with over 40 dosage forms, covering a wide spectrum of diseases ranging from communicable, non-communicable, common and emerging diseases to even rare diseases.

Cipla invites candidates for its API Virgonagar Plant in Bangalore.

Post: Quality Assurance/Quality Control Executive

Cipla to Start Biotech Manufacturing Facility at South Africa

  • Posted on: 12 July 2016
  • By: PharmaTutor News

Cipla Ltd announced this week that its proposed biotech subsidiary in South Africa will invest just over R1.3 billion into the country's first state-of-the-art biotech manufacturing facility, for the production of biosimilars. Cipla Ltd is a global pharmaceutical company and owner of Cipla Medpro, South Africa’s third largest pharmaceutical manufacturer, as well as Cipla BioTec, a biotechnology company focused on affordable and accessible biopharmaceuticals.

Cipla receive US FDA approval for Lopinavir, Ritonavir oral pellets to treat AIDS in infants

  • Posted on: 11 June 2015
  • By: Shalini.Sharma

The US FDA has granted approval to Cipla's Lopinavir, Ritonavir (LPV/r) 40mg/ 10 mg oral pellets for paediatric specific treatment of HIV in infants. Cipla was working for many years in collaboration with Diana Gibb, professor of epidemiology, senior programme leader and honorary consultant paediatrician at Medical Research Council Clinical Trials Unit at UCL (University College London) towards development of this novel child-friendly formulation which has been approved by US FDA under the President’s Emergency Plan for AIDS Relief (PEPFAR) programme. This product is a first step in making accessible more modern and appropriately formulated treatment available to the most vulnerable of HIV patients – young children.

Cipla signs agreement with Serum Institute to introduce flu vaccine Nasovac-S in India

  • Posted on: 1 June 2015
  • By: Shalini.Sharma

The pharmaceutical major Cipla Limited has signed an pact with Serum Institute of India Ltd (SII) to exclusively market flu vaccine Nasovac-S in India. Under this agreement, SII will develop and manufacture the vaccine, and Cipla will market it in India. The vaccine will be manufactured in Serum’s world class production facilities approved by the WHO.